Product Description
H1 and H5 Influenza Hemagglutinin Plasmid Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01405885)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| FLU-002 | P1 |
Completed |
Influenza, Human |
2012-08-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|